Globus Medical Logo
US3795772082
A1J2LY
GMED

Globus Medical

Forecast

The analysts' average price target is €79.74 (+30.29%). The median is €76.10 (+24.35%).

Buy
  26
Hold
  10
Sell
  1

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Globus Medical receives CE marking for imaging system Excelsius3D and begins EU/UK commercialization

    Globus Medical has received CE marking for commercial distribution of its mobile imaging system Excelsius3D in the European Union and the United Kingdom. Excelsius3D combines 3D cone‑beam CT, 2D fluoroscopy and digital radiography and can be integrated into the robotic navigation system ExcelsiusGPS to enable intraoperative imaging and robot‑assisted navigation. The system was already cleared in the US in 2021 via 510(k); the stock rose slightly in after‑hours trading. » More on de.investing.com


  • Globus Medical acquires digital-health company Higgs Boson Health

    Globus Medical announced the acquisition of Higgs Boson Health, a Durham (North Carolina)-based digital-health startup spun out of Duke University. Higgs Boson brings software developers and AI scientists and will be integrated into Globus Medical’s division for digital health technologies. The technology will become part of the “Surgical Intelligence” pillar and be used across the entire patient journey; financial details were not disclosed. » More on de.investing.com


  • Globus Medical exceeds revenue forecast in Q2, raises non‑GAAP earnings target

    Globus Medical reported Q2 revenue of $789.6 million and a record non‑GAAP EPS of $1.34; GAAP EPS of $1.10 matched analysts’ estimates. Adjusted EBITDA margin rose to 35.4% and the company generated strong operating cash flow of $412.1 million in the first half of the year. Globus reaffirmed full‑year revenue guidance of $3.18–3.22 billion and raised its non‑GAAP EPS outlook to $4.95–5.05; the stock reacted positively in after‑hours trading. Management cited margin expansion, market‑share gains in spine and trauma, and continued investments in the product pipeline and enabling technologies. » More on de.investing.com


  • Madison Small Cap Fund sells Globus Medical after valuation surpasses its estimate

    Madison Small Cap Fund liquidated its multi-year position in Globus Medical, saying the company's post-acquisition success and robotics adoption pushed market value above its intrinsic estimate. The fund cited a market cap near $12 billion and an intrinsic value of $85 per share versus a roughly $90 market price, and said it will reallocate to smaller opportunities. Fund performance and broader market context (value outperformance, AI/geopolitical volatility) were noted in the Q1 2026 letter. » More on finance.yahoo.com


  • Wells Fargo cuts price target on Globus Medical after strong Q1 results

    Wells Fargo lowered its price target on Globus Medical to $103 from $104 while maintaining an Overweight rating despite the company reporting fiscal Q1 sales and EPS above consensus. Globus posted worldwide net sales of $759.9 million, up 27.0% (25.5% cc), and base business sales excluding Nevro of $677.2 million, up 13.2% (11.2% cc). Management cited record Q1 earnings, organic revenue growth driven by share gains and procedural volume in core spine, and expansion of the customer base through Enabling Technologies. » More on finance.yahoo.com

Financials

In the last quarter, Globus Medical had revenue of €674.25M and net profit of €124.63M

(EUR) September 2026
YoY
Revenue 674.25M 2.89%
Gross profit 468.62M 13.00%
Net profit 124.63M 22.94%
EBITDA 223.93M 22.16%

Fundamentals

Metric Value
Market capitalization
€8.08B
Number of shares
132.47M
52-week high/low
€92.41 - €60.72
Dividends No
Beta
0.96
P/E ratio
16.16
PEG ratio
0.49
P/B ratio
1.87
P/S ratio
2.82

Company profile

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Name
Globus Medical
CEO
Keith W. Pfeil
Headquarters Audubon, pa
USA
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
08/03/2012
Employees 6,000

Ticker symbols

Exchange Symbol
NYSE
GMED
Frankfurt
GM0N.F
DĂĽsseldorf
GM0N.DU
MĂĽnchen
GM0N.MU
🍪

Parqet  uses cookies. Learn more